news

 

January 2019 AMMIC platform works on developing novel drugs for rare diseases

 
AMMIC platform works on developing novel drugs for rare diseases

AROMICS is one of the participants on the project AMMIC: an accelerator platform for the development of new therapies in minoritary disease in Catalonia. The project is partially supported by the Operative Program FEDER in Catalonia 2014-2020.

AMMIC project is lead by IUCT and integrated by Esteve, Minoryx, Aromics, BCN peptides, Aniling, qGenomics and the research centre VHIR.

The project is part of the NEXTHEALTH, the RIS3CAT community for the innovation in Health coordinated by BIOCAT and supported by Catalan Government through ACC1Ó.